Oppenheimer & Co. Inc. Boosts Position in Hologic, Inc. (NASDAQ:HOLX)

Oppenheimer & Co. Inc. lifted its position in Hologic, Inc. (NASDAQ:HOLX) by 2.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 20,275 shares of the medical equipment provider’s stock after purchasing an additional 500 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Hologic were worth $1,505,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Innealta Capital LLC purchased a new stake in shares of Hologic during the 2nd quarter valued at approximately $25,000. iA Global Asset Management Inc. purchased a new stake in Hologic in the first quarter valued at $37,000. Mather Group LLC. acquired a new position in shares of Hologic in the 1st quarter valued at $48,000. Massmutual Trust Co. FSB ADV increased its position in shares of Hologic by 24.7% during the 1st quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock worth $54,000 after purchasing an additional 137 shares during the last quarter. Finally, Toth Financial Advisory Corp increased its position in shares of Hologic by 81.1% during the 1st quarter. Toth Financial Advisory Corp now owns 775 shares of the medical equipment provider’s stock worth $60,000 after purchasing an additional 347 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Trading Down 0.8 %

NASDAQ HOLX opened at $82.00 on Wednesday. Hologic, Inc. has a 52 week low of $64.02 and a 52 week high of $84.67. The firm has a 50 day moving average of $80.36 and a two-hundred day moving average of $76.92. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $19.14 billion, a PE ratio of 41.84, a price-to-earnings-growth ratio of 2.53 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, beating the consensus estimate of $1.02 by $0.04. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. Hologic’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.93 earnings per share. As a group, research analysts expect that Hologic, Inc. will post 4.09 EPS for the current fiscal year.

Insider Buying and Selling

In other Hologic news, insider Brandon Schnittker sold 476 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the sale, the insider now owns 3,735 shares of the company’s stock, valued at $310,415.85. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, insider Brandon Schnittker sold 476 shares of the stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the transaction, the insider now directly owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Stephen P. Macmillan sold 3,672 shares of the business’s stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total transaction of $294,237.36. Following the completion of the sale, the chief executive officer now directly owns 1,157,562 shares of the company’s stock, valued at $92,755,443.06. The disclosure for this sale can be found here. Insiders sold a total of 18,280 shares of company stock worth $1,469,973 over the last 90 days. 1.75% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $82.00 target price on shares of Hologic in a research note on Friday, August 16th. StockNews.com cut shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. JPMorgan Chase & Co. boosted their target price on Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a research report on Tuesday, July 30th. Needham & Company LLC restated a “buy” rating and set a $90.00 price target on shares of Hologic in a research report on Tuesday. Finally, Evercore ISI boosted their price objective on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a report on Tuesday, July 30th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $87.60.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.